131 related articles for article (PubMed ID: 9179691)
1. Absence of RET proto-oncogene mutations in a father and son with pheochromocytoma and pancreatic islet cell tumor.
Kawasaki T; Tomita Y; Takahashi H; Takeda M; Tanaka H; Tamiya Y; Takahashi K
Int J Urol; 1997 Mar; 4(2):169-71. PubMed ID: 9179691
[TBL] [Abstract][Full Text] [Related]
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
3. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
Yoshimoto K; Kimura T; Tanaka C; Moritani M; Iwahana H; Itakura M
Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
[TBL] [Abstract][Full Text] [Related]
4. Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive single-strand conformation polymorphism analysis and direct sequencing.
Komminoth P; Kunz E; Hiort O; Schröder S; Matias-Guiu X; Christiansen G; Roth J; Heitz PU
Am J Pathol; 1994 Oct; 145(4):922-9. PubMed ID: 7943181
[TBL] [Abstract][Full Text] [Related]
5. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene.
Brauch H; Hoeppner W; Jähnig H; Wöhl T; Engelhardt D; Spelsberg F; Ritter MM
J Clin Endocrinol Metab; 1997 Dec; 82(12):4101-4. PubMed ID: 9398721
[TBL] [Abstract][Full Text] [Related]
6. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
Neumann HP; Eng C; Mulligan LM; Glavac D; Zäuner I; Ponder BA; Crossey PA; Maher ER; Brauch H
JAMA; 1995 Oct; 274(14):1149-51. PubMed ID: 7563486
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
Ponder BA
Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
[No Abstract] [Full Text] [Related]
9. Alterations of RET oncogene in human adrenal tumors.
Lin SR; Yang YC; Tsai JH; Hsu CH
Jpn J Cancer Res; 1998 Jun; 89(6):634-40. PubMed ID: 9703361
[TBL] [Abstract][Full Text] [Related]
10. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
[TBL] [Abstract][Full Text] [Related]
11. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.
Woodward ER; Eng C; McMahon R; Voutilainen R; Affara NA; Ponder BA; Maher ER
Hum Mol Genet; 1997 Jul; 6(7):1051-6. PubMed ID: 9215674
[TBL] [Abstract][Full Text] [Related]
12. Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas.
Chew SL; Lavender P; Jain A; Weber A; Ross RJ; Wass JA; Besser GM; Clark AJ
Clin Endocrinol (Oxf); 1995 Jan; 42(1):17-21. PubMed ID: 7889627
[TBL] [Abstract][Full Text] [Related]
13. RET proto-oncogene point mutations in sporadic neuroendocrine tumors.
Komminoth P; Roth J; Muletta-Feurer S; Saremaslani P; Seelentag WK; Heitz PU
J Clin Endocrinol Metab; 1996 Jun; 81(6):2041-6. PubMed ID: 8964826
[TBL] [Abstract][Full Text] [Related]
14. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
[TBL] [Abstract][Full Text] [Related]
15. Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients.
Januszewicz A; Neumann HP; Loń I; Szmigielski C; Symonides B; Kabat M; Apel TW; Wocial B; Lapiński M; Januszewicz W
J Hypertens; 2000 Aug; 18(8):1019-23. PubMed ID: 10953992
[TBL] [Abstract][Full Text] [Related]
16. Germ line mutation in the RET proto-oncogene associated with familial multiple endocrine neoplasia type 2B: a case report.
Ishida O; Zeki K; Morimoto I; Yamamoto S; Fujihira T; Eto S
Jpn J Clin Oncol; 1995 Jun; 25(3):104-8. PubMed ID: 7596047
[TBL] [Abstract][Full Text] [Related]
17. RET mutation screening in sporadic pheochromocytoma.
Arnold A
J Clin Endocrinol Metab; 1996 Jan; 81(1):430. PubMed ID: 8550789
[No Abstract] [Full Text] [Related]
18. Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.
Egawa S; Futami H; Takasaki K; Iihara M; Okamoto T; Kanbe M; Ohi T; Saio Y; Miyauchi A; Takiyama Y; Koga M; Miyanaga K; Inoue K; Mitsuyama S; Nomura Y; Takei H; Mugiya S; Ishida O; Zeze F; Shakutsui S; Inoue H; Oya H; Yoshimura A; Ishizuka S; Yamaguchi K
Jpn J Clin Oncol; 1998 Oct; 28(10):590-6. PubMed ID: 9839497
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the RET protooncogene in sporadic pheochromocytomas.
Lindor NM; Honchel R; Khosla S; Thibodeau SN
J Clin Endocrinol Metab; 1995 Feb; 80(2):627-9. PubMed ID: 7852530
[TBL] [Abstract][Full Text] [Related]
20. A novel Val648Ile substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin-producing pheochromocytoma.
Nunes AB; Ezabella MC; Pereira AC; Krieger JE; Toledo SP
J Clin Endocrinol Metab; 2002 Dec; 87(12):5658-61. PubMed ID: 12466368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
